Evidence map›Paper›PMID 31391070›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

NR1B2 suppress kidney renal clear cell carcinoma (KIRC) progression by regulation of LATS 1/2-YAP signaling.

Lei Yin, Wenjia Li, Guangchun Wang, Heng Shi, Keyi Wang, Huan Yang, Bo Peng

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Lei YinDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Wenjia LiShanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China.
Guangchun WangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Heng ShiDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Keyi WangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China.
Huan YangDepartment of Urology, Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. yhpz123@163.com.
Bo PengDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine in Tongji University, Shanghai, China. pengbo6908@163.com.
Tongji University · CNFudan University · CNShanghai Tenth People's Hospital · CNTongji Hospital · CN

Funding

Innovation Foundation of Huazhong University of Science and Technology 1802030National Natural Science Foundation of China 31670772National Natural Science Foundation of China 81500534National Natural Science Foundation of China 81870517National Research Foundation for the Doctoral Program of Higher Education of China 20130142120072Natural Science Foundation of Shanghai 18140900302
6 · The paper itself

Abstract

backgroundKidney Renal Clear Cell Carcinoma (KIRC) accounts for 75% of all renal cancers. Previous study had conflict evidences regarding NR1B2 role in cancer, and its expression and biological role in KIRC remained unclear. Our aims were to characterize the role of NR1B2 in KIRC.

methodsNR1B2 expression in TCGA database were analyzed. Clinical KIRC samples were examined by RT-PCR, western blot and tissue microarray (TMA). The relationship between NR1B2 expression and the clinical characteristics were evaluated. KIRC cell line were stably overexpressed NR1B2 or with an NR1B2 knocked down using lentivirus system. The cells were analyzed by migration and invasion assay, then injected into nude mice to assess tumor growth and metastasis. EMT marker expression and LATS 1/2-YAP pathway demonstration were detected by the TCGA database and western blot.

resultsThe expression of NR1B2 in KIRC was significantly down-regulated in the TCGA database and our clinical samples. Moreover, NR1B2 expression negatively correlated with tumor stage and positively correlated with overall and disease-free survival rate. Univariate and multivariate analyses indicated the expression level of NR1B2 could be used as an independent factor for predicting the prognosis of KIRC. Overexpression NR1B2 significantly inhibited and knockdown NR1B2 markedly promoted KIRC cell invasion and metastasis both in vitro and in vivo. Mechanistic investigations revealed that NR1B2 might be a tumor suppressor to inhibit EMT through the LATS1/2-YAP pathway.

conclusionsour results defined NR1B2 as a tumor suppressor in KIRC that restricted EMT by the LATS1/2-YAP pathway.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, Renal CellCell Cycle ProteinsCell Line, TumorDatabases, GeneticDisease Models, AnimalDisease ProgressionHumansKaplan-Meier EstimateKidney NeoplasmsMicePrognosisProtein BindingProtein Serine-Threonine KinasesReceptors, N-Methyl-D-AspartateBiomarkers, TumorCell Cycle ProteinsLATS1 protein, humanLATS2 protein, humanProtein Serine-Threonine KinasesReceptors, N-Methyl-D-AspartateTranscription FactorsTumor Suppressor ProteinsYY1AP1 protein, humanEMTKidney renal clear cell carcinomaLATSNR1B2YAP

Identifiers

PMID31391070
PMCPMC6686564
OpenAlexW2964956702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.